Fig. 9: Clinical trials studying KRAS-targeted therapies in CRC patients.

Chronogram of clinical trials that include at least one of the 106 compounds shown in Fig. 8, evaluating their response in patients with solid malignancies, including CRC. The horizontal segments represent the planned start and finalization dates of the clinical trials. On the left side of each bar, the target KRAS mutation or KRAS-related protein is indicated. On the right side, the KRAS-related drug or drugs are indicated. Clinical trials have been organized in different panels by study phase, and colored based on the study status. The white dots indicate the latest information update. The vertical gray bar indicates the current date. Data were obtained from the Clinical Trials database (https://clinicaltrials.gov), retrieved as detailed in “Methods”.